Orforglipron
moderate riskAlso: LY3502970 · Oral GLP-1 small molecule
Orforglipron is a non-peptide, oral, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Not technically a peptide but included due to its positioning in the GLP-1 space. Phase III trials show ~14.7% weight loss — competitive with injectable semaglutide. Potential to democratize GLP-1 access via oral dosing.
Reported Benefits
Weight loss
Phase III ATTAIN-1: 14.7% body weight loss at 36 weeks — comparable to semaglutide without injection.
Mechanism of Action
Non-peptide small molecule binding to GLP-1 receptor extracellular domain at the same site as peptide GLP-1 agonists; full receptor agonism with oral bioavailability — solves the peptide delivery challenge.
Key Clinical Studies
Wharton et al. (Phase 2b) (2023)
Phase II RCT · n=272
Dose-dependent weight loss 9.4–14.7% at 26 weeks
The Oral Advantage
Solving the injection barrier for GLP-1 therapy could dramatically expand market access and patient adherence. Orforglipron’s non-peptide nature avoids the food absorption variability issue with oral semaglutide (Rybelsus requires strict fasting protocol). If Phase III confirms, it could reshape the GLP-1 market.
Not a peptide, but included because practitioners in this space need comparative context.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •Hepatic enzyme elevation
Contraindications
- •Pregnancy
- •Severe hepatic impairment
Drug Interactions
- •Insulin/sulfonylureas
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Orforglipron?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →